Generic Topical And Transdermal Products Complex Generics- Sep. 25-26, 2019

Strategies for Generic Topical Product Development (7of35) Complex Generics– Sep. 25-26, 2019

U.S. Food and Drug Administration

Questions and Answers (9of35) Complex Generic Drugs – Sep. 25-26, 2019

U.S. Food and Drug Administration

Quality for Transdermal Delivery Systems (8of35) Complex Generic Drugs – Sep. 25-26, 2019

U.S. Food and Drug Administration

Questions and Answers (22of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Pre-ANDA Program Update (2of35) Complex Generics– Sep. 25-26, 2019

U.S. Food and Drug Administration

Comparative Analyses: Injectable Combination Products (21of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Considerations of Particle Analysis (12of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Strategies to Demonstrate Complex API Sameness (10of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

BE Approaches for Long Acting Drug Products (14of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Questions and Answers (17of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

PSG Recommendations and Updates for OINDPs (23of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Physiologically-based Pharmacokinetic Modeling (32of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

What Constitutes Complex Drug-Device Combination (18of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Quantitative Methods and Modeling (29of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Questions and Answers (13of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Quantitative Clinical Pharmacology in LA Injectables (34of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Complex Generics: Topical Products, Part 1

U.S. Food and Drug Administration

Overview of Comparative Analyses - Clinical Perspective (19of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration

Comparative Analyses: Device and User Interface (25of35) Complex Generics– Sep. 25-26, 2019

U.S. Food and Drug Administration

Dose-Scale Analysis in Pharmacodynamic Equivalence (31of35) Complex Generics – Sep. 25-26, 2019

U.S. Food and Drug Administration